First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?
作者信息
Hofman Paul
机构信息
Université Côte d'Azur, CHU Nice, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France.
Université Côte d'Azur, CNRS, INSERM, IRCAN, FHU OncoAge, Nice, France.
出版信息
Transl Lung Cancer Res. 2019 Oct;8(5):728-730. doi: 10.21037/tlcr.2019.04.18.
Abstract
摘要
相似文献
1
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?晚期或转移性非小细胞肺癌患者的一线免疫治疗……肿瘤细胞上PD-L1表达的最终阈值是多少？
Transl Lung Cancer Res. 2019 Oct;8(5):728-730. doi: 10.21037/tlcr.2019.04.18.
2
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
3
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.晚期非小细胞肺癌的转移部位并不影响 PD-L1 表达。
Lung Cancer. 2019 Jun;132:36-38. doi: 10.1016/j.lungcan.2019.04.009. Epub 2019 Apr 8.
4
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?肿瘤突变负荷评估作为肺癌患者免疫治疗的预测生物标志物：是否已准备好进入黄金时代？
Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04.
5
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.通过免疫组织化学评估程序性死亡受体配体1（PD-L1）状态：肺癌患者治疗策略面临的挑战与前景
Virchows Arch. 2016 May;468(5):511-25. doi: 10.1007/s00428-016-1910-4. Epub 2016 Feb 25.
6
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.纳武利尤单抗或帕博利珠单抗治疗晚期非小细胞肺癌患者的肿瘤PD-L1表达及临床结局：台湾地区的真实世界数据
J Cancer. 2018 Apr 19;9(10):1813-1820. doi: 10.7150/jca.24985. eCollection 2018.
7
Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy.局部晚期 III 期非小细胞肺癌患者经放化疗治疗的长期生存及免疫治疗的展望。
Radiol Oncol. 2018 Feb 21;52(3):281-288. doi: 10.2478/raon-2018-0009.
8
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.检测晚期非小细胞肺癌患者循环肿瘤细胞和白细胞中的 PD-L1。
Ann Oncol. 2018 Jan 1;29(1):193-199. doi: 10.1093/annonc/mdx636.
9
[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].[支气管活检中PD-L1状态免疫组化评估的问题及当前局限]
Bull Cancer. 2016 Apr;103(4):368-80. doi: 10.1016/j.bulcan.2016.01.014. Epub 2016 Feb 23.
10
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.如何将免疫治疗作为晚期/转移性非小细胞肺癌的一线治疗进行优化。
Ann Oncol. 2019 Jun 1;30(6):884-896. doi: 10.1093/annonc/mdz109.
引用本文的文献
1
Fluorescence Lifetime Imaging Enables In Vivo Quantification of PD-L1 Expression and Intertumoral Heterogeneity.荧光寿命成像可实现体内程序性死亡受体配体1（PD-L1）表达及肿瘤间异质性的定量分析。
Cancer Res. 2025 Feb 1;85(3):618-632. doi: 10.1158/0008-5472.CAN-24-0880.
2
quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging.使用荧光寿命成像技术对肿瘤中程序性死亡配体-1表达异质性进行定量分析。
Res Sq. 2023 Oct 23:rs.3.rs-3222037. doi: 10.21203/rs.3.rs-3222037/v1.
3
Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model.在转移性非小细胞肺癌患者中识别适合原发性肿瘤切除的最佳候选者：一项基于人群的预测模型
Transl Lung Cancer Res. 2021 Jan;10(1):279-291. doi: 10.21037/tlcr-20-709.
4
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.在转移性前列腺癌中完善免疫肿瘤学方法：超越当前的局限性。
Curr Treat Options Oncol. 2021 Jan 12;22(2):13. doi: 10.1007/s11864-020-00808-x.
本文引用的文献
1
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.非小细胞肺癌中单区域组织、多区域组织和血液肿瘤突变负荷的相关性。
J Immunother Cancer. 2019 Apr 3;7(1):98. doi: 10.1186/s40425-019-0581-5.
2
Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray.程序性细胞死亡配体 1 免疫组织化学：手术标本、活检和组织微阵列之间的一致性研究。
Clin Lung Cancer. 2019 Jul;20(4):258-262.e1. doi: 10.1016/j.cllc.2019.02.012. Epub 2019 Feb 27.
3
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.PD-L1 表达和肿瘤突变负担是大多数癌症的独立生物标志物。
JCI Insight. 2019 Mar 21;4(6). doi: 10.1172/jci.insight.126908.
4
PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.常规非小细胞肺癌样本中的 PD-L1 表达：一个集中实验室 1 年经验的结果和关键问题。
J Clin Pathol. 2019 Jun;72(6):412-417. doi: 10.1136/jclinpath-2019-205732. Epub 2019 Mar 7.
5
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.非小细胞肺癌中程序性死亡配体1免疫组织化学
J Thorac Dis. 2019 Jan;11(Suppl 1):S89-S101. doi: 10.21037/jtd.2018.12.103.
6
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
7
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?肿瘤突变负荷评估作为肺癌患者免疫治疗的预测生物标志物：是否已准备好进入黄金时代？
Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04.
8
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.PD-L1 检测试剂 22C3 和 SP263 在考虑临床相关截断值时在非小细胞肺癌中不可互换：不同培训的病理学家进行的克隆间评估。
Am J Surg Pathol. 2018 Oct;42(10):1384-1389. doi: 10.1097/PAS.0000000000001105.
9
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
10
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.利用 22C3 抗程序性死亡配体 1 抗体检测非小细胞肺癌患者细胞学样本中的程序性死亡配体 1 表达。
Cancer Cytopathol. 2018 Apr;126(4):264-274. doi: 10.1002/cncy.21977. Epub 2018 Feb 7.
Zotero 插件